JP2015526696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526696A5 JP2015526696A5 JP2015513220A JP2015513220A JP2015526696A5 JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5 JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5
- Authority
- JP
- Japan
- Prior art keywords
- cer
- galcer
- glc
- sphingosine
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BPLYVSYSBPLDOA-WVILEFPPSA-N N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-WVILEFPPSA-N 0.000 claims 96
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 78
- SXPRAKSDHOEHIG-ZESVVUHVSA-N N-docosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC SXPRAKSDHOEHIG-ZESVVUHVSA-N 0.000 claims 54
- BTUSGZZCQZACPT-YYZTVXDQSA-N hexadecasphing-4-enine Chemical compound CCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO BTUSGZZCQZACPT-YYZTVXDQSA-N 0.000 claims 48
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 claims 42
- 150000002632 lipids Chemical class 0.000 claims 38
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims 36
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 claims 30
- YMYQEDCYNANIPI-NMJNODIHSA-N beta-D-galactosyl-N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YMYQEDCYNANIPI-NMJNODIHSA-N 0.000 claims 30
- 239000000523 sample Substances 0.000 claims 28
- 238000000034 method Methods 0.000 claims 25
- KEPQASGDXIEOIL-UHFFFAOYSA-N (2S,3R)-N-(docosanoate)-1,3-dihydroxy-2-amino-octadeca-4-(E)-ene Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC KEPQASGDXIEOIL-UHFFFAOYSA-N 0.000 claims 24
- ZJVVOYPTFQEGPH-UHFFFAOYSA-N 102917-80-6 Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC ZJVVOYPTFQEGPH-UHFFFAOYSA-N 0.000 claims 24
- 101100480513 Caenorhabditis elegans tag-52 gene Proteins 0.000 claims 24
- KEPQASGDXIEOIL-GLQCRSEXSA-N N-docosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC KEPQASGDXIEOIL-GLQCRSEXSA-N 0.000 claims 24
- ZJVVOYPTFQEGPH-AUTSUKAISA-N N-tetracosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC ZJVVOYPTFQEGPH-AUTSUKAISA-N 0.000 claims 24
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 23
- 230000003584 silencer Effects 0.000 claims 21
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 18
- VJLLLMIZEJJZTE-DKZZKAIRSA-N N-(hexadecanoyl)-beta-D-galactosylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VJLLLMIZEJJZTE-DKZZKAIRSA-N 0.000 claims 18
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims 18
- HLIJNIKSBCIDGO-QKLMXXKVSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-hexadecanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HLIJNIKSBCIDGO-QKLMXXKVSA-N 0.000 claims 18
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 18
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 16
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 13
- YIGARKIIFOHVPF-YMBRMJIUSA-N 1-(beta-D-galactosyl)-N-behenoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YIGARKIIFOHVPF-YMBRMJIUSA-N 0.000 claims 12
- 101100079986 Caenorhabditis elegans nrfl-1 gene Proteins 0.000 claims 12
- 101100084165 Caenorhabditis elegans prdx-2 gene Proteins 0.000 claims 12
- VOZHMDQUIRUFQW-LOTHNZFDSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-octadecanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 VOZHMDQUIRUFQW-LOTHNZFDSA-N 0.000 claims 12
- KDEYEEYMIPNKIJ-OGIIFMLESA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-tetracosanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDEYEEYMIPNKIJ-OGIIFMLESA-N 0.000 claims 12
- VJLLLMIZEJJZTE-NNTBDIJYSA-N beta-D-glucosyl-N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VJLLLMIZEJJZTE-NNTBDIJYSA-N 0.000 claims 12
- YMYQEDCYNANIPI-DYJXBSQNSA-N beta-D-glucosyl-N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YMYQEDCYNANIPI-DYJXBSQNSA-N 0.000 claims 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 12
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims 12
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims 12
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 12
- 239000003524 antilipemic agent Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 6
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 6
- 102000007592 Apolipoproteins Human genes 0.000 claims 6
- 108010071619 Apolipoproteins Proteins 0.000 claims 6
- 101100480514 Caenorhabditis elegans tag-53 gene Proteins 0.000 claims 6
- CJROVRTUSFQVMR-GVOPMEMSSA-N N-hexacosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC CJROVRTUSFQVMR-GVOPMEMSSA-N 0.000 claims 6
- XWBWIAOWSABHFI-NUKVNZTCSA-N N-icosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC XWBWIAOWSABHFI-NUKVNZTCSA-N 0.000 claims 6
- QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 claims 6
- DOIOUJPHIXRQFM-JHCBZXGBSA-N beta-D-galactosyl-N-(hexacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOIOUJPHIXRQFM-JHCBZXGBSA-N 0.000 claims 6
- DFELABABMXOKTD-PWUIYKNCSA-N beta-D-galactosyl-N-eicosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DFELABABMXOKTD-PWUIYKNCSA-N 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 6
- YHEDRJPUIRMZMP-ZWKOTPCHSA-N sphinganine 1-phosphate Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)COP(O)(O)=O YHEDRJPUIRMZMP-ZWKOTPCHSA-N 0.000 claims 6
- 102000000853 LDL receptors Human genes 0.000 claims 4
- 108010001831 LDL receptors Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 238000012360 testing method Methods 0.000 claims 3
- 238000008214 LDL Cholesterol Methods 0.000 claims 2
- 229940127355 PCSK9 Inhibitors Drugs 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000004777 loss-of-function mutation Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102200057358 rs11591147 Human genes 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101150094724 PCSK9 gene Proteins 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000005305 interferometry Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 230000009437 off-target effect Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000010287 polarization Effects 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651569P | 2012-05-25 | 2012-05-25 | |
| US61/651,569 | 2012-05-25 | ||
| EP12169517.5A EP2667197B1 (en) | 2012-05-25 | 2012-05-25 | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition |
| EP12169517.5 | 2012-05-25 | ||
| PCT/EP2013/060816 WO2013175016A1 (en) | 2012-05-25 | 2013-05-24 | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526696A JP2015526696A (ja) | 2015-09-10 |
| JP2015526696A5 true JP2015526696A5 (cg-RX-API-DMAC7.html) | 2016-11-10 |
Family
ID=46146755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513220A Pending JP2015526696A (ja) | 2012-05-25 | 2013-05-24 | プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160146842A2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2667197B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015526696A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104508488A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2875419A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2552371T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013175016A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2014135696A1 (en) * | 2013-03-08 | 2014-09-12 | Zora Biosciences Oy | Non-high density lipoprotein derived cvd markers |
| WO2017097852A2 (en) * | 2015-12-07 | 2017-06-15 | Zora Biosciences Oy | Use of ceramides and lpls in diagnosing cvd |
| EP3515950A4 (en) | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
| CN114062581A (zh) * | 2017-12-14 | 2022-02-18 | 江苏豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CN109504737A (zh) * | 2018-11-23 | 2019-03-22 | 黄河科技学院 | 一种体外筛选pcsk9抑制剂的方法 |
| WO2022089486A1 (zh) * | 2020-10-28 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 抑制PCSK9基因表达的siRNA及其修饰物与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007127192A2 (en) * | 2006-04-24 | 2007-11-08 | Duke University | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| US20100041102A1 (en) | 2006-11-07 | 2010-02-18 | Ayesha Sitlani | Antagonists of pcsk9 |
| CA2681428A1 (en) * | 2007-04-13 | 2008-10-23 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| SG2013014352A (en) | 2007-10-26 | 2014-09-26 | Merck Sharp & Dohme | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| DE112010004626T5 (de) * | 2009-12-01 | 2012-10-18 | Metanomics Health Gmbh | Mittel und Verfahren zur Diagnose von multipler Sklerose |
| EP3502707A1 (en) * | 2010-01-29 | 2019-06-26 | metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| NO2385374T3 (cg-RX-API-DMAC7.html) * | 2010-05-05 | 2014-06-07 | ||
| EP2583107A2 (en) * | 2010-06-20 | 2013-04-24 | Zora Biosciences OY | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| EP2592422A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
-
2012
- 2012-05-25 ES ES12169517.5T patent/ES2552371T3/es active Active
- 2012-05-25 EP EP12169517.5A patent/EP2667197B1/en not_active Not-in-force
-
2013
- 2013-05-24 JP JP2015513220A patent/JP2015526696A/ja active Pending
- 2013-05-24 WO PCT/EP2013/060816 patent/WO2013175016A1/en not_active Ceased
- 2013-05-24 CN CN201380027083.7A patent/CN104508488A/zh active Pending
- 2013-05-24 US US14/403,075 patent/US20160146842A2/en not_active Abandoned
- 2013-05-24 CA CA2875419A patent/CA2875419A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526696A5 (cg-RX-API-DMAC7.html) | ||
| Menghini et al. | MiR-216a: a link between endothelial dysfunction and autophagy | |
| De Miguel et al. | Exercise plasma boosts memory and dampens brain inflammation via clusterin | |
| JP6388284B2 (ja) | スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー | |
| JP6388283B2 (ja) | スタチン治療を受けていない冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー | |
| Wang et al. | Human PAD4 regulates histone arginine methylation levels via demethylimination | |
| Mracek et al. | Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients | |
| CN103154742B (zh) | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 | |
| Lee et al. | Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance | |
| Atalar et al. | Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes | |
| Baranyi et al. | Nitric oxide-related biological pathways in patients with major depression | |
| Marshall et al. | Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes | |
| CN104769434B (zh) | 用于2型糖尿病的生物标志物 | |
| JP2014532886A5 (cg-RX-API-DMAC7.html) | ||
| CN103502820B (zh) | 用于他汀引发的肌肉毒性的灵敏检测的生物标志物 | |
| Zhang et al. | KLF4-PFKFB3-driven glycolysis is essential for phenotypic switching of vascular smooth muscle cells | |
| Zhang et al. | Exosomal circEZH2_005, an intestinal injury biomarker, alleviates intestinal ischemia/reperfusion injury by mediating Gprc5a signaling | |
| Walss-Bass et al. | X-aptamer technology identifies C4A and ApoB in blood as potential markers for schizophrenia | |
| JP2017535756A5 (cg-RX-API-DMAC7.html) | ||
| EP2667197B1 (en) | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition | |
| Anzalone et al. | IL-17A-associated IKK-α signaling induced TSLP production in epithelial cells of COPD patients | |
| Shirsath et al. | HSP60 knockdown exerts differential response in endothelial cells and monocyte derived macrophages during atherogenic transformation | |
| Doppler et al. | Noncanonical atherosclerosis as the driving force in tricuspid aortic valve associated aneurysms-A trace collection | |
| Kawasaki et al. | Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19 | |
| Boi et al. | Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions |